Literature DB >> 2898364

Thyroid uptake of MIBG in Sipple's syndrome.

R Perdrisot1, V Rohmer, J J Lejeune, J C Bigorgne, P Jallet.   

Abstract

The use of the adrenomedullary tracer metaiodobenzylguanidine (MIBG) in the localization of medullary carcinoma of the thyroid (MCT) is based on the embryologic relationship of the APUD cell series. The authors report the results obtained in six patients with MCT: two had Sipple's syndrome and four sporadic forms of the disease. MIBG uptake by the CMT was observed in both cases of Sipple's syndrome and in only one of the other cases. Scintigraphic detection seems to depend on the clinical features, the size of the tumour and also on the part played by its secretory function. MCT would thus appear to be more frequently visualized by MIBG in cases of Sipple's syndrome than in sporadic cases. The procedure therefore seems useful in the diagnosis, follow up and even in the treatment of MCT.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898364     DOI: 10.1007/bf00252616

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  14 in total

1.  [Localization of medullary cancer of the thyroid gland by scintigraphy using meta-iodo-benzylguanidine].

Authors:  F Getin; V Rohmer; J P Saint Andre; P Jallet; J C Bigorgne
Journal:  Presse Med       Date:  1985-03-09       Impact factor: 1.228

2.  Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.

Authors:  A L Steiner; A D Goodman; S R Powers
Journal:  Medicine (Baltimore)       Date:  1968-09       Impact factor: 1.889

3.  Medullary (solid) carcinoma of the thyroid gland: an analysis of the M. D. Anderson hospital experience with patients with the tumor, its special features, and its histogenesis.

Authors:  C S Hill; M L Ibanez; N A Samaan; M J Ahearn; R L Clark
Journal:  Medicine (Baltimore)       Date:  1973-03       Impact factor: 1.889

4.  Imaging of medullary thyroid cancer with 131I-MIBG.

Authors:  K Endo; K Shiomi; K Kasagi; J Konishi; K Torizuka; K Nakao; H Tanimura
Journal:  Lancet       Date:  1984-07-28       Impact factor: 79.321

5.  131I-MIBG uptake by medullary carcinoma of thyroid.

Authors:  G J Poston; A M Thomas; D W MacDonald; J A Lynn; J P Lavender
Journal:  Lancet       Date:  1985-09-07       Impact factor: 79.321

Review 6.  The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept.

Authors:  A G Pearse
Journal:  J Histochem Cytochem       Date:  1969-05       Impact factor: 2.479

7.  Poor results with technetium-99m (V) DMS and iodine-131 MIBG in the imaging of medullary thyroid carcinoma.

Authors:  T E Hilditch; J M Connell; A T Elliot; T Murray; N S Reed
Journal:  J Nucl Med       Date:  1986-07       Impact factor: 10.057

8.  Mucosal neuroma, pheochromocytoma and medullary thyroid carcinoma: multiple endocrine neoplasia type 3.

Authors:  M R Khairi; R N Dexter; N J Burzynski; C C Johnston
Journal:  Medicine (Baltimore)       Date:  1975-03       Impact factor: 1.889

9.  Uptake of 131I-MIBG by medullary carcinoma of thyroid in familial cases.

Authors:  G Coutris; J N Talbot; G Kabla; C Calmettes; G Milhaud
Journal:  Eur J Nucl Med       Date:  1986

10.  Scintigraphic localization of pheochromocytoma.

Authors:  J C Sisson; M S Frager; T W Valk; M D Gross; D P Swanson; D M Wieland; M C Tobes; W H Beierwaltes; N W Thompson
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

View more
  1 in total

1.  The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience.

Authors:  L Troncone; V Rufini; P Montemaggi; F M Danza; A Lasorella; R Mastrangelo
Journal:  Eur J Nucl Med       Date:  1990
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.